The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease.

Exclusion Criteria

• •Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies and excluding seasonal allergies).
• •Subjects with a history of substance abuse or dependence or a positive urine screen for drugs of abuse.
• •A history of regular alcohol consumption exceeding 7 drinks/week for women or 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening.
• •Subjects with a documented allergy to methylphenidate or one of the product excipients.
• •Subjects with any medical condition affecting drug absorption (e.g. gastrectomy).
• •Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.
• •Use of a monoamine oxidase inhibitor or other interacting medication within the preceding 14 days or 5 half-lives (whichever is longer).
• •History of sensitivity to heparin or heparin-induced thrombocytopenia.